How to buy Inozyme Pharma (INZY) stock

Inozyme Pharma, Inc is a biotechnology business based in the US. Inozyme Pharma shares (INZY) are listed on the NASDAQ and all prices are listed in US Dollars. Inozyme Pharma employs 38 staff and has a market cap (total outstanding shares value) of 0.00.

Inozyme Pharma stock price (NASDAQ: INZY)

Use our graph to track the performance of INZY stocks over time.

Inozyme Pharma shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$16.36
52-week range	$14.51 - $31.65
50-day moving average	$17.17
200-day moving average	$19.50
Wall St. target price	$36.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.11

Buy Inozyme Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Inozyme Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Inozyme Pharma, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Inozyme Pharma price performance over time

Historical closes compared with the close of $16.36 from 2021-05-28

1 week (2021-07-15)	N/A
1 month (2021-06-25)	-3.48%
3 months (2021-04-26)	-14.30%
6 months (2021-01-22)	N/A

1 year (2020-07-22)	N/A
2 years (2019-07-22)	N/A
3 years (2018-07-22)	N/A
5 years (2016-07-22)	N/A

Inozyme Pharma financials

Gross profit TTM	$0
Return on assets TTM	-37.39%
Return on equity TTM	-64.23%
Profit margin	0%
Book value	$6.34
Market capitalisation	$446.9 million

TTM: trailing 12 months

Shorting Inozyme Pharma shares

There are currently 1.3 million Inozyme Pharma shares held short by investors – that's known as Inozyme Pharma's "short interest". This figure is 25.8% up from 1.0 million last month.

There are a few different ways that this level of interest in shorting Inozyme Pharma shares can be evaluated.

Inozyme Pharma's "short interest ratio" (SIR)

Inozyme Pharma's "short interest ratio" (SIR) is the quantity of Inozyme Pharma shares currently shorted divided by the average quantity of Inozyme Pharma shares traded daily (recently around 95907.29550479). Inozyme Pharma's SIR currently stands at 13.57. In other words for every 100,000 Inozyme Pharma shares traded daily on the market, roughly 13570 shares are currently held short.

However Inozyme Pharma's short interest can also be evaluated against the total number of Inozyme Pharma shares, or, against the total number of tradable Inozyme Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inozyme Pharma's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Inozyme Pharma shares in existence, roughly 60 shares are currently held short) or 0.2763% of the tradable shares (for every 100,000 tradable Inozyme Pharma shares, roughly 276 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Inozyme Pharma.

Find out more about how you can short Inozyme Pharma stock.

Inozyme Pharma share dividends

We're not expecting Inozyme Pharma to pay a dividend over the next 12 months.

Inozyme Pharma overview

Inozyme Pharma, Inc. , a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. .

Frequently asked questions

What percentage of Inozyme Pharma is owned by insiders or institutions?
Currently 8.892% of Inozyme Pharma shares are held by insiders and 94.725% by institutions. How many people work for Inozyme Pharma?
Latest data suggests 38 work at Inozyme Pharma. When does the fiscal year end for Inozyme Pharma?
Inozyme Pharma's fiscal year ends in December. Where is Inozyme Pharma based?
Inozyme Pharma's address is: 321 Summer Street, Boston, MA, United States, 02210 What is Inozyme Pharma's ISIN number?
Inozyme Pharma's international securities identification number is: US45790W1080